melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery metabolic

DEXA - Bone Mineral Density Scan
Obesity is a condition of pandemic proportions in the modern world.  A myriad of conditions ranging from cardiovascular disease, type-2 diabetes, cancer, and even depression have been linked to obesity (Bloom SR, 2008). Research into the mechanisms and treatment of obesity is an ongoing area of interest to many in the pharmaceutical and academic communities.  Animal models have proven useful in studying hte effects of compounds on diet-induced obesity (DIO) (Hildebrand AL, 2003; Levin BE, 2000). 

In this study, we characterize a mouse model using a pharmacological approach at treating diet-induced obesity.  At Melior, this assay serves as a platform for a number of additional acute and chronic disorders consistent with diet-induced obesity changes in humans. 

 

Figure 1- Bone Density:

    

There were significant reductions in Bone Mineral Density (A) in Vehicle + High Fat Diet (Veh+HFD) and Sibutramine + High Fat Diet (Sib+HFD) - treated animals compared to Vehicle+Control (Veh+Control) -treated animals.  There were no significant changes in Bone Mineral Content (B) or Bone Area (C) between all groups.  Data are mean ± SEM; *p<0.05, **p<0.01 compared to Veh+Control treated animals. 

 

Figure 2- Tissue Area and Mass:

          

There were significant increases in Tissue Area (A) and Total Tissue Mass (B) in both the Veh+HFD and Sib+HFD- treated animals compared to Veh+Control treated animals. There were no significant differences between the Veh+HFD and Sib+HFD-treated groups. Data are mean ± SEM; *p<0.05, ***p<0.001 compared to Veh+Control treated animals. 

 

Figure 3- Fat Vs. Lean Percent and Mass:

         

                                               

There were significant increases in % Fat Tissue (A) and Fat Mass (B) in both Veh+HFD and Sib+HFD-treated groups.  There were significant decreases in %Lean Tissue (C) in both Veh+HFD and Sib+HFD-treated groups compared to Veh+Control treated groups.  There were no significant changes in Lean Mass (D) between any of the groups. Data are mean ± SEM; *p<0.05, ***p<0.001 compared to Veh+Control treated animals. 

 

If you are interested in learning more about DEXA - Bone Mineral Density Scan, please contact models@meliordiscovery.com to start the conversation today.